Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03532217
Title Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

prostate adenocarcinoma

Therapies

Ipilimumab + Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.